REG - Venture Life Group - Director/PDMR Shareholding

Venture LifeAnnouncement

09/01/2020 16:30

RNS Number : 3561Z
Venture Life Group PLC
09 January 2020
 


9 January 2020
Venture Life Group plc
("Venture Life" or the "Group")
Director dealings
Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces that Sharon Collins, Chief Commercial Officer, purchased 283,600 ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary Shares") at a price of 35.75 pence per share on 8 January 2020 and a further 71,020 Ordinary Shares at a price of 35.12 pence per share on 9 January 2020.
Following these purchases, Sharon Collins is interested in 2,019,953 Ordinary Shares, representing approximately 2.41% of the issued share capital of the Company.
 
For further information, please contact:
 




Venture Life Group plc


+44(0) 1344 578004


 




Jerry Randall, Chief Executive Officer


 


 




 


 




Cenkos Securities plc (Nomad and Broker)


+44(0)20 7397 8900


 




Mark Connelly / Stephen Keys / Cameron MacRitchie (Corporate Finance)


 


 




Russell Kerr / Michael Johnson (Sales)


 


 




 


 


 




  Alma PR


 


 +44(0)20 3405 0205


 




  Hilary Buchanan / Helena Bogle / Jessica Joynson


 


 


 




 

 
 
 





 About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in both the UK and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare and proctology and dermo-cosmetics for addressing the signs of ageing.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK these are supplied direct by the company, outside of the UK they are supplied by the Group's international distribution partners. 
Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.
 
The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:




 1


Details of the person discharging managerial responsibilities / person closely associated 




a)


Name


Sharon Collins




2


Reason for the notification




a)


Position/status


Chief Commercial Officer




b)


Initial notification /Amendment


Initial Notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 




a)


Name


Venture Life Group plc




b)


LEI


213800S8CZUPLAB2KC70




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument


Ordinary Shares of 0.3p each in Venture Life Group plc




b)


Identification code 


GB00BFPM8908




c)


Nature of the transaction 


Purchase of Ordinary Shares




d)
 


Price and volumes


 




Price


Volume




1.   £0.3575
2.   £0.3512


1.   283,600
2.   71,020




 




d)
 


Aggregated information 
- Aggregated volume

- Price


 
N/A - single trades  




e)


Date of the transaction 


1.   8th January 2020
2.   9th January 2020




f)


Place of the transaction


London Stock Exchange




 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHFLFFRLSIAIII